Korean J Dermatol.  2022 May;60(4):220-227.

Improvements in Health-Related Quality of Life in Patients with Psoriatic Arthritis and Moderate-to-Severe Psoriasis Receiving Secukinumab: A Retrospective Study

• Hong YJ
• Go GM
• Kim M

Abstract

Background
Psoriasis is a relapsing inflammatory skin disorder that can affect the nails and joints. Psoriatic arthritis (PsA) occurs in up to 30% of patients with psoriasis, leading to chronic articular pain, and impairing quality of life. Secukinumab is a human monoclonal antibody targeting interleukin-17A that has been shown to effectively improve the clinical signs and symptoms of PsA.
Objective
To evaluate the effect of secukinumab on health-related quality of life (HRQOL) in Korean PsA patients.
Methods
We retrospectively investigated the medical records and psoriasis area and severity index (PASI) scores of 13 patients with PsA who completed the psoriatic arthritis impact of disease 12-item questionnaire (PsAID-12) before and 3 months after receiving secukinumab treatment between October 2019 and August 2021 in Yeouido St.Mary’s Hospital.
Results
At week 12, significant reductions in the total and each item PsAID-12 and mean PASI score were observed (p＜0.01). The mean decrease of total PsAID-12 score was 4.8 (95% confidence interval [CI], 3.74∼5.86), with the greatest improvement observed in the item of ‘embarrassment’ (7.15; 95% CI, 5.59∼8.72). Of the 13 patients, 11 (84.6%) and 5 (38.5%) achieved PASI75 and PASI90 response, respectively.
Conclusion
This study showed that secukinumab improves the HRQOL of patients with PsA, implying a positive influence of secukinumab on patients’ physical and mental status in a real-world clinical setting.

Keyword

Psoriatic arthritis; Psoriatic arthritis impact of disease; Quality of life; Retrospective study